Radiochemical, Computational, and Spectroscopic Evaluation of High-Denticity Desferrioxamine Derivatives DFO2 and DFO2p toward an Ideal Zirconium-89 Chelate Platform.

Desferrioxamine (DFO) has long been considered the gold standard chelator for incorporating [89Zr]Zr4+ in radiopharmaceuticals for positron emission tomography (PET) imaging. To improve the stability of DFO with zirconium-89 and to expand its coordination sphere to enable binding of large therapeutic radiometals, we have synthesized the highest denticity DFO derivatives to date: dodecadentate DFO2 and DFO2p. In this study, we describe the synthesis and characterization of a novel DFO-based chelator, DFO2p, which is comprised of two DFO strands connected by an p-NO2-phenyl linker and therefore contains double the chelating moieties of DFO (potential coordination number up to 12 vs 6). The chelator DFO2p offers an optimized synthesis comprised of only a single reaction step and improves water solubility relative to DFO2, but the shorter linker reduces molecular flexibility. Both DFO2 and DFO2p, each with 6 potential hydroxamate ligands, are able to reach a more energetically favorable 8-coordinate environment for Zr(IV) than DFO. The zirconium(IV) coordination environment of these complexes were evaluated by a combination of density functional theory (DFT) calculations and synchrotron spectroscopy (extended X-ray absorption fine structure), which suggest the inner-coordination sphere of zirconium(IV) to be comprised of the outermost four hydroxamate ligands. These results also confirm a single Zr(IV) in each chelator, and the hydroxide ligands which complete the coordination sphere of Zr(IV)-DFO are absent from Zr(IV)-DFO2 and Zr(IV)-DFO2p. Radiochemical stability studies with zirconium-89 revealed the order of real-world stability to be DFO2 > DFO2p ≫ DFO. The zirconium-89 complexes of these new high-denticity chelators were found to be far more stable than DFO, and the decreased molecular flexibility of DFO2p, relative to DFO2, could explain its decreased stability, relative to DFO2.

[1]  E. Price,et al.  Design, Synthesis, and Evaluation of DFO-Em: A Modular Chelator with Octadentate Chelation for Optimal Zirconium-89 Radiochemistry. , 2022, Inorganic chemistry.

[2]  A. Rogachev,et al.  Novel Chelating Agents for Zirconium-89-Positron Emission Tomography (PET) Imaging: Synthesis, DFT Calculation, Radiolabeling, and In Vitro and In Vivo Complex Stability , 2022, ACS omega.

[3]  G. Fricker,et al.  Toward Optimized 89Zr-Immuno-PET: Side-by-Side Comparison of [89Zr]Zr-DFO-, [89Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [89Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable? , 2022, Pharmaceutics.

[4]  Dijie Liu,et al.  Synthesis and Evaluation of Diaza-Crown Ether-Backboned Chelator Containing Hydroxamate Groups for Zr-89 Chelation Chemistry. , 2022, Bioorganic & medicinal chemistry letters.

[5]  F. Bénard,et al.  Trastuzumab-conjugated oxine-based ligand for [89Zr]Zr4+ immunoPET. , 2022, Journal of inorganic biochemistry.

[6]  G. Fricker,et al.  Side-by-Side Comparison of Five Chelators for 89Zr-Labeling of Biomolecules: Investigation of Chemical/Radiochemical Properties and Complex Stability , 2021, Cancers.

[7]  H. Stephan,et al.  [nat/89Zr][Zr(pypa)]: Thermodynamically Stable and Kinetically Inert Binary Nonadentate Complex for Radiopharmaceutical Applications. , 2021, Inorganic chemistry.

[8]  M. Schwaiger,et al.  A Semi Rigid Novel Hydroxamate AMPED-Based Ligand for 89Zr PET Imaging , 2021, Molecules.

[9]  G. Gasser,et al.  The Race for Hydroxamate-Based Zirconium-89 Chelators , 2021, Cancers.

[10]  A. Baldi,et al.  Thermodynamic Stability and Speciation of Ga(III) and Zr(IV) Complexes with High-Denticity Hydroxamate Chelators , 2021, Inorganic chemistry.

[11]  A. Windhorst,et al.  Comparison of analytical methods for antibody conjugates with application in nuclear imaging - Report from the trenches. , 2021, Nuclear medicine and biology.

[12]  R. Boellaard,et al.  Study of 89Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non–Small Cell Lung Cancer , 2021, The Journal of Nuclear Medicine.

[13]  F. Rösch,et al.  Development and in vitro evaluation of new bifunctional 89Zr-chelators based on the 6-amino-1,4-diazepane scaffold for immuno-PET applications. , 2021, Nuclear medicine and biology.

[14]  P. Choyke,et al.  In Vitro and In Vivo Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody Anetumab , 2021, Cancer biotherapy & radiopharmaceuticals.

[15]  H. Fonge,et al.  89Zr-Labeled Domain II-Specific scFv-Fc ImmunoPET Probe for Imaging Epidermal Growth Factor Receptor In Vivo , 2021, Cancers.

[16]  R. Boellaard,et al.  The Role of 89Zr-Immuno-PET in Navigating and Derisking the Development of Biopharmaceuticals , 2020, The Journal of Nuclear Medicine.

[17]  Elaheh Khozeimeh Sarbisheh,et al.  Structural Characterization of the Solution Chemistry of Zirconium(IV) Desferrioxamine: A Coordination Sphere Completed by Hydroxides. , 2020, Inorganic chemistry.

[18]  G. V. van Dongen,et al.  Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical 89Zr-immuno-PET , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  Elaheh Khozeimeh Sarbisheh,et al.  A High-Denticity Chelator Based on Desferrioxamine for Enhanced Coordination of Zirconium-89. , 2020, Inorganic chemistry.

[20]  H. Fonge,et al.  Production and Semi-Automated Processing of 89Zr Using a Commercially Available TRASIS MiniAiO Module , 2020, Molecules.

[21]  B. Guérin,et al.  Promising Performance of 4HMS, a New Zirconium-89 Octadendate Chelator , 2020, ACS omega.

[22]  Jason S. Lewis,et al.  A Systematic Evaluation of Antibody Modification and 89Zr-Radiolabeling for Optimized Immuno-PET. , 2020, Bioconjugate chemistry.

[23]  J. Holland Predicting the Thermodynamic Stability of Zirconium Radiotracers. , 2020, Inorganic chemistry.

[24]  F. Bénard,et al.  Evaluation of the Tetrakis(3-Hydroxy-4-Pyridinone) Ligand THPN with Zirconium(IV): Thermodynamic Solution Studies, Bifunctionalization, and in Vivo Assessment of Macromolecular 89Zr-THPN-Conjugates. , 2019, Inorganic chemistry.

[25]  D. Sokaras,et al.  X-ray Absorption Spectroscopy Investigations of Copper(II) Coordination in the Human Amyloid β Peptide. , 2019, Inorganic chemistry.

[26]  W. Oyen,et al.  Positron Emission Tomography/Computed Tomography with 89Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion. , 2018, European urology.

[27]  R. Reilly,et al.  Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with 89Zr-Labeled Trastuzumab-DM1: A Comparison with 89Zr-Labeled Trastuzumab. , 2018, Molecular pharmaceutics.

[28]  Jason S. Lewis,et al.  Tumor-Specific Zr-89 Immuno-PET Imaging in a Human Bladder Cancer Model , 2018, Molecular Imaging and Biology.

[29]  F. Bénard,et al.  Synthesis and evaluation of bifunctional tetrahydroxamate chelators for labeling antibodies with 89Zr for imaging with positron emission tomography. , 2018, Bioorganic & medicinal chemistry letters.

[30]  T. Wadas,et al.  Recent Advances in Zirconium-89 Chelator Development , 2018, Molecules.

[31]  B. Wängler,et al.  Rational Design, Development, and Stability Assessment of a Macrocyclic Four‐Hydroxamate‐Bearing Bifunctional Chelating Agent for 89Zr , 2017, ChemMedChem.

[32]  Justin J. Wilson,et al.  Multifunctional Desferrichrome Analogues as Versatile 89Zr(IV) Chelators for ImmunoPET Probe Development. , 2017, Molecular pharmaceutics.

[33]  Lars Konermann,et al.  Addressing a Common Misconception: Ammonium Acetate as Neutral pH “Buffer” for Native Electrospray Mass Spectrometry , 2017, Journal of The American Society for Mass Spectrometry.

[34]  T. Aweda,et al.  Production of Zr-89 using sputtered yttrium coin targets 89Zr using sputtered yttrium coin targets. , 2017, Nuclear medicine and biology.

[35]  Jason S. Lewis,et al.  89Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection , 2017, The Journal of Nuclear Medicine.

[36]  R. Codd,et al.  Octadentate Zirconium(IV)-Loaded Macrocycles with Varied Stoichiometry Assembled From Hydroxamic Acid Monomers using Metal-Templated Synthesis. , 2017, Inorganic chemistry.

[37]  Danny F. Martinez,et al.  First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake , 2016, The Journal of Nuclear Medicine.

[38]  G. V. van Dongen,et al.  Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[39]  Marc C. Huisman,et al.  Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials? , 2016, Front. Pharmacol..

[40]  Nathaniel T Kenton,et al.  Macrocycle-Based Hydroxamate Ligands for Complexation and Immunoconjugation of 89Zirconium for Positron Emission Tomography (PET) Imaging. , 2016, ChemPlusChem.

[41]  Simon-Peter Williams,et al.  Evaluation of a 3-hydroxypyridin-2-one (2,3-HOPO) Based Macrocyclic Chelator for 89Zr4+ and Its Use for ImmunoPET Imaging of HER2 Positive Model of Ovarian Carcinoma in Mice , 2016, Theranostics.

[42]  Jason S. Lewis,et al.  p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPET. , 2015, Bioconjugate chemistry.

[43]  C. Decristoforo,et al.  Novel Bifunctional Cyclic Chelator for 89Zr Labeling–Radiolabeling and Targeting Properties of RGD Conjugates , 2015, Molecular pharmaceutics.

[44]  Jason S. Lewis,et al.  The bioconjugation and radiosynthesis of 89Zr-DFO-labeled antibodies. , 2015, Journal of visualized experiments : JoVE.

[45]  Jason S. Lewis,et al.  What a Difference a Carbon Makes: H4octapa vs H4C3octapa, Ligands for In-111 and Lu-177 Radiochemistry , 2014, Inorganic chemistry.

[46]  Y. Lee,et al.  Propylene cross-bridged macrocyclic bifunctional chelator: a new design for facile bioconjugation and robust (64)Cu complex stability. , 2014, Journal of medicinal chemistry.

[47]  Jason S. Lewis,et al.  Alternative Chelator for 89Zr Radiopharmaceuticals: Radiolabeling and Evaluation of 3,4,3-(LI-1,2-HOPO) , 2014, Journal of medicinal chemistry.

[48]  M. Brechbiel,et al.  Rational design, synthesis, and evaluation of tetrahydroxamic acid chelators for stable complexation of zirconium(IV). , 2014, Chemistry.

[49]  Jason S. Lewis,et al.  Applying PET to Broaden the Diagnostic Utility of the Clinically Validated CA19.9 Serum Biomarker for Oncology , 2013, The Journal of Nuclear Medicine.

[50]  Donald G. Truhlar,et al.  M11-L: A Local Density Functional That Provides Improved Accuracy for Electronic Structure Calculations in Chemistry and Physics , 2012 .

[51]  T. Nayak,et al.  PET and MRI of Metastatic Peritoneal and Pulmonary Colorectal Cancer in Mice with Human Epidermal Growth Factor Receptor 1–Targeted 89Zr-Labeled Panitumumab , 2012, The Journal of Nuclear Medicine.

[52]  R. Weissleder,et al.  Modular Strategy for the Construction of Radiometalated Antibodies for Positron Emission Tomography Based on Inverse Electron Demand Diels–Alder Click Chemistry , 2011, Bioconjugate chemistry.

[53]  D. Abou,et al.  In vivo biodistribution and accumulation of 89Zr in mice. , 2011, Nuclear medicine and biology.

[54]  Yin Zhang,et al.  PET tracers based on Zirconium-89. , 2011, Current radiopharmaceuticals.

[55]  S. Larson,et al.  89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo , 2010, The Journal of Nuclear Medicine.

[56]  P. L. Jager,et al.  Biodistribution of 89Zr‐trastuzumab and PET Imaging of HER2‐Positive Lesions in Patients With Metastatic Breast Cancer , 2010, Clinical pharmacology and therapeutics.

[57]  C. Saturnino,et al.  Chemical and biological properties of toxic metals and use of chelating agents for the pharmacological treatment of metal poisoning , 2010, Archives of Toxicology.

[58]  Valerie A Longo,et al.  Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/neu Expression in Mice Using 89Zr-DFO-Trastuzumab , 2010, PloS one.

[59]  Jason S. Lewis,et al.  Standardized methods for the production of high specific-activity zirconium-89. , 2009, Nuclear medicine and biology.

[60]  Johan R de Jong,et al.  Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging , 2009, Journal of Nuclear Medicine.

[61]  O. Visser,et al.  Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[62]  B. Delley From molecules to solids with the DMol3 approach , 2000 .

[63]  R. Prince,et al.  The Molybdenum Site of Sulfite Oxidase: A Comparison of Wild-Type and the Cysteine 207 to Serine Mutant Using X-ray Absorption Spectroscopy , 1996 .

[64]  Andreas Klamt,et al.  Incorporation of solvent effects into density functional calculations of molecular energies and geometries , 1995 .

[65]  B. Delley An all‐electron numerical method for solving the local density functional for polyatomic molecules , 1990 .

[66]  D. Rosenthal,et al.  Treatment of iron overload in adults with continuous parenteral desferrioxamine. , 1977, The American journal of medicine.